0001420520 false 12/31 2021 Q3 0001420520 2021-01-01 2021-09-30 0001420520 2021-10-27 0001420520 2021-09-30 0001420520 2020-12-31 0001420520 2021-07-01 2021-09-30 0001420520 2020-07-01 2020-09-30 0001420520 2020-01-01 2020-09-30 0001420520 us-gaap:CommonStockMember 2020-12-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001420520 us-gaap:RetainedEarningsMember 2020-12-31 0001420520 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001420520 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001420520 2021-01-01 2021-03-31 0001420520 us-gaap:CommonStockMember 2021-03-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001420520 us-gaap:RetainedEarningsMember 2021-03-31 0001420520 2021-03-31 0001420520 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001420520 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001420520 2021-04-01 2021-06-30 0001420520 us-gaap:CommonStockMember 2021-06-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001420520 us-gaap:RetainedEarningsMember 2021-06-30 0001420520 2021-06-30 0001420520 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001420520 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001420520 us-gaap:CommonStockMember 2021-09-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001420520 us-gaap:RetainedEarningsMember 2021-09-30 0001420520 us-gaap:CommonStockMember 2019-12-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001420520 us-gaap:RetainedEarningsMember 2019-12-31 0001420520 2019-12-31 0001420520 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001420520 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001420520 2020-01-01 2020-03-31 0001420520 us-gaap:CommonStockMember 2020-03-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001420520 us-gaap:RetainedEarningsMember 2020-03-31 0001420520 2020-03-31 0001420520 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001420520 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001420520 2020-04-01 2020-06-30 0001420520 us-gaap:CommonStockMember 2020-06-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001420520 us-gaap:RetainedEarningsMember 2020-06-30 0001420520 2020-06-30 0001420520 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001420520 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001420520 us-gaap:CommonStockMember 2020-09-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001420520 us-gaap:RetainedEarningsMember 2020-09-30 0001420520 2020-09-30 0001420520 srt:NorthAmericaMember 2021-07-01 2021-09-30 0001420520 srt:NorthAmericaMember 2020-07-01 2020-09-30 0001420520 srt:NorthAmericaMember 2021-01-01 2021-09-30 0001420520 srt:NorthAmericaMember 2020-01-01 2020-09-30 0001420520 srt:AsiaPacificMember 2021-07-01 2021-09-30 0001420520 srt:AsiaPacificMember 2020-07-01 2020-09-30 0001420520 srt:AsiaPacificMember 2021-01-01 2021-09-30 0001420520 srt:AsiaPacificMember 2020-01-01 2020-09-30 0001420520 us-gaap:TransferredAtPointInTimeMember 2021-07-01 2021-09-30 0001420520 us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0001420520 us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-09-30 0001420520 us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-09-30 0001420520 us-gaap:TransferredOverTimeMember 2021-07-01 2021-09-30 0001420520 us-gaap:TransferredOverTimeMember 2020-01-01 2020-09-30 0001420520 us-gaap:TransferredOverTimeMember 2021-01-01 2021-09-30 0001420520 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001420520 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001420520 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001420520 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001420520 atom:UnvestedRestrictedStockMember 2021-07-01 2021-09-30 0001420520 atom:UnvestedRestrictedStockMember 2021-01-01 2021-09-30 0001420520 atom:UnvestedRestrictedStockMember 2020-07-01 2020-09-30 0001420520 atom:UnvestedRestrictedStockMember 2020-01-01 2020-09-30 0001420520 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001420520 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001420520 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001420520 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001420520 atom:LosGatosCaMember 2020-08-31 0001420520 atom:LosGatosCaMember 2021-01-31 0001420520 atom:LosGatosCaMember 2021-09-30 0001420520 atom:TempeAzMember 2021-03-31 0001420520 atom:TempeAzMember 2021-09-30 0001420520 atom:ToolLeaseMember 2021-08-01 0001420520 atom:ToolLeaseMember 2021-08-02 2021-09-30 0001420520 atom:ToolLeaseMember 2020-01-01 2020-09-30 0001420520 atom:ToolLeaseMember 2021-09-30 0001420520 us-gaap:WarrantMember 2020-12-31 0001420520 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001420520 us-gaap:WarrantMember 2021-09-30 0001420520 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001420520 us-gaap:WarrantMember 2021-01-01 2021-01-31 0001420520 2021-01-01 2021-01-31 0001420520 atom:Plan2017Member 2021-09-30 0001420520 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001420520 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001420520 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001420520 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001420520 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001420520 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001420520 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001420520 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001420520 atom:SellingAndMarketingMember 2021-07-01 2021-09-30 0001420520 atom:SellingAndMarketingMember 2020-07-01 2020-09-30 0001420520 atom:SellingAndMarketingMember 2021-01-01 2021-09-30 0001420520 atom:SellingAndMarketingMember 2020-01-01 2020-09-30 0001420520 us-gaap:StockOptionMember 2021-09-30 0001420520 us-gaap:StockOptionMember 2021-01-01 2021-09-30 0001420520 us-gaap:StockOptionMember 2021-07-01 2021-09-30 0001420520 us-gaap:StockOptionMember 2020-07-01 2020-09-30 0001420520 us-gaap:StockOptionMember 2020-01-01 2020-09-30 0001420520 us-gaap:StockOptionMember 2020-12-31 0001420520 us-gaap:RestrictedStockMember 2020-12-31 0001420520 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001420520 us-gaap:RestrictedStockMember 2021-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2021.

 

or

 

☐ Transition Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

 

Commission file number: 001-37850

 

ATOMERA INCORPORATED

(Exact name of registrant as specified in its charter)

 

Delaware

30-0509586

(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

 

750 University Avenue, Suite 280

Los Gatos, California 95032

(Address, including zip code, of registrant’s principal executive offices)

 

(408) 442-5248

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock: Par value $0.001 ATOM Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated Filer ☐
Non-accelerated Filer ☒ Smaller reporting company ☒
Emerging Growth Company ☒  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by checkmark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act: Yes ☐ No ☒

 

The number of outstanding shares of the Registrant’s Common Stock, par value $.001 per share, as of October 27, 2021 was 23,157,878.

 

 

     

 

Atomera Incorporated

 

Index

 

    Page
PART I. Financial Information  
     
Item 1. Financial Statements 3
     
  Condensed Balance Sheets – September 30, 2021 (unaudited) and December 31, 2020 3
     
  Unaudited Condensed Statements of Operations - For the Three and Nine Months Ended September 30, 2021 and 2020 4
     
  Unaudited Condensed Statements of Stockholders’ Equity - For the Three and Nine Months Ended September 30, 2021 and 2020 5
     
  Unaudited Condensed Statements of Cash Flows - For the Nine Months Ended September 30, 2021 and 2020 6
     
  Notes to the Unaudited Condensed Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 18
     
Item 4. Controls and Procedures 18
     
PART II. Other Information  
   
Item 1A. Risk Factors 19
     
Item 5. Other Information 19
     
Item 6. Exhibits 19
     
Signatures 20

 

 

 

  2  

 

 

PART I. Financial Information

 

Item 1. Financial Statements

 

Atomera Incorporated

Condensed Balance Sheets

(in thousands, except per share data)

 

                 
             
    September 30,     December 31,  
    2021     2020  
    (Unaudited)        
ASSETS                
                 
Current assets:                
Cash and cash equivalents   $ 31,789     $ 37,942  
Prepaid expenses and other current assets     429       132  
Total current assets     32,218       38,074  
                 
Property and equipment, net     208       153  
Operating lease right-of-use asset     950       705  
Financing lease right-of-use asset     6,170       –  
Long-term prepaid rent     –       450  
Long-term prepaid maintenance and supplies     91       –  
Security deposit     14       13  
                 
Total assets   $ 39,651     $ 39,395  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                 
Current liabilities:                
Accounts payable   $ 321     $ 442  
Accrued expenses     315       211  
Accrued payroll related expenses     434       705  
Current operating lease liability     214       90  
Current financing lease liability     1,621       –  
Total current liabilities     2,905       1,448  
                 
Long-term operating lease liability     809       602  
Long-term financing lease liability     4,455       –  
                 
Total liabilities     8,169       2,050  
                 
Commitments and contingencies (see Note 10)     –       –  
                 
Stockholders’ equity:                
Preferred stock $0.001 par value, authorized 2,500 shares; none issued and outstanding at September 30, 2021 and December 31, 2020     –       –  
Common stock: $0.001 par value, authorized 47,500 shares; 23,145 and 22,375 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively;     23       22  
Additional paid-in capital     193,148       187,463  
Accumulated deficit     (161,689 )     (150,140 )
Total stockholders’ equity     31,482       37,345  
                 
Total liabilities and stockholders’ equity   $ 39,651     $ 39,395  

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

  3  

 

 

Atomera Incorporated

Condensed Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

                                 
                         
   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
    2021     2020     2021     2020  
Revenue   $ –     $ –     $ 400     $ 62  
Cost of revenue     –       –       –       (13 )
Gross margin   $ –     $ –     $ 400     $ 49  
                                 
Operating expenses                                
Research and development     2,232       2,049       6,530       6,197  
General and administrative     1,637       1,322       4,656       4,247  
Selling and marketing     267       208       670       648  
Total operating expenses     4,136       3,579       11,856       11,092  
                                 
Loss from operations     (4,136 )     (3,579 )     (11,456 )     (11,043 )
                                 
Other income (expense)                                
Interest income     2       1       7       41  
Interest expense     (52 )     –       (52 )     –  
Total other income (expense), net     (50 )     1       (45 )     41  
                                 
Net loss before income taxes     (4,186 )     (3,578 )     (11,501 )     (11,002 )
Provision for income taxes     17       –       48       –  
                                 
Net loss   $ (4,203 )     (3,578 )   $ (11,549 )     (11,002 )
Net loss per common share, basic and diluted   $ (0.19 )     (0.19 )   $ (0.52 )     (0.61 )
                                 
Weighted average number of common shares outstanding, basic and diluted     22,629       19,337       22,405       18,028  

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

  4  

 

 

Atomera Incorporated

Statements of Stockholders’ Equity

For the Three and Nine Months Ended September 30, 2021 and 2020

(Unaudited)

(in thousands) 

 

                               
    Common Stock     Additional
Paid-in 		    Accumulated     Total
Stockholders’ 		 
    Shares     Amount     Capital     Deficit     Equity  
Balance January 1, 2021     22,375     $ 22     $ 187,463     $ (150,140 )   $ 37,345  
Stock-based compensation     71       –       731       –       731  
At-the-market sale of stock, net of commissions and expenses     14       –       243       –       243  
Stock option exercise     398       1       2,514       –       2,515  
Warrant Exercise     223       –       –       –       –  
Forfeited restricted stock awards     (54 )     –       –       –       –  
Net loss     –       –       –       (3,620 )     (3,620 )
Balance March 31, 2021     23,027     $ 23     $ 190,951     $ (153,760 )   $ 37,214  
Stock-based compensation     18       –       847       –       847  
Stock option exercise     59       –       354       –       354  
Net loss     –       –       –       (3,726 )     (3,726 )
Balance at June 30, 2021     23,104     $ 23     $ 192,152     $ (157,486 )   $ 34,689  
Stock option exercise     49       –       240       –       240  
Stock-based compensation     –       –       756       –       756  
Forfeited restricted stock awards     (8 )     –       –       –       –  
Net loss     –       –       –       (4,203 )     (4,203 )
Balance at September 30, 2021     23,145     $ 23     $ 193,148     $ (161,689 )   $ 31,482

 

  

                               
    Common Stock     Additional
Paid-in 		    Accumulated     Total Stockholders’  
    Shares     Amount     Capital     Deficit     Equity  
Balance January 1, 2020     17,117     $ 17     $ 149,017     $ (135,262 )   $ 13,772  
Stock-based compensation     420       1       628       –       629  
Warrant exercise     189       –       164       –       164  
Warrant modification     –       –       139       –       139  
Net loss     –       –       –       (3,645 )     (3,645 )
Balance March 31, 2020     17,726     $ 18     $ 149,948     $ (138,907 )   $ 11,059  
Underwritten public offering of common stock, net of commissions and expenses     2,024       2       9,393       –       9,395  
Stock option exercise     33       –       137       –       137  
Stock-based compensation     43       –       766       –       766  
Net loss     –       –       –       (3,779 )     (3,779 )
Balance June 30, 2020     19,826     $ 20     $ 160,244     $ (142,686 )   $ 17,578  
At-the-market sale of stock, net of commissions and expenses     846       1       8,519       –       8,520  
Stock option exercise     103       –       645       –       645  
Stock-based compensation     –       –       829       –       829  
Warrant exercise     196       –       738       –       738  
Net loss     –       –       –       (3,578 )     (3,578 )
Balance September 30, 2020     20,971     $ 21     $ 170,975     $ (146,264 )   $ 24,732  

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

  5  

 

 

Atomera Incorporated

Condensed Statements of Cash Flows

(Unaudited)

(in thousands)

 

             
    Nine Months Ended
September 30, 		 
    2021     2020  
CASH FLOWS FROM OPERATING ACTIVITIES                
Net Loss   $ (11,549 )   $ (11,002 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     47       32  
Operating lease right of use asset amortization     136       107  
Financing lease right of use asset amortization     211       –  
Stock-based compensation     2,334       2,224  
Warrant modification expense     –       139  
Non cash interest expense     52       –  
Changes in operating assets and liabilities:                
Prepaid expenses and other current assets     (297 )     (49 )
Long-term prepaid rent     –       (450 )
Accounts payable     (121 )     248  
Accrued expenses     104       89  
Accrued payroll expenses     (271 )     (308 )
Operating lease liability     (50 )     (110 )
Deferred revenue     –       (37 )
Net cash used in operating activities     (9,404 )     (9,117 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES                
Acquisition of property and equipment     (102 )     (56 )
Net cash used in investing activities     (102 )     (56 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES                
Proceeds from underwritten public offering, net of commission and expenses     –       9,395  
Proceeds from at-the-market sale of stock, net of commissions and expenses     243       8,520  
Proceeds from exercise of warrants     –       902  
Proceeds from exercise of stock options     3,110       782  
Net cash provided by financing activities     3,353       19,599  
                 
Net increase (decrease) in cash and cash equivalents     (6,153 )     10,426  
                 
Cash and cash equivalents at beginning of period     37,942       14,871  
                 
Cash and cash equivalents at end of period   $ 31,789     $ 25,297  
                 
Supplemental information:                
Cash paid for interest   $ –     $ –  
Cash paid for taxes   $ 66     $ –  

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

  6  

 

 

ATOMERA INCORPORATED

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2021 and 2020

 

1. NATURE OF OPERATIONS

 

Atomera Incorporated (“Atomera” or the “Company”) was incorporated in the state of Delaware in March 2007 under the name MEARS Technologies, Inc. and is engaged in the development, commercialization and licensing of proprietary processes and technologies for the semiconductor industry. On January 12, 2016, the Company changed its name to Atomera Incorporated.

 

Atomera is an early-stage company, having only recently begun limited revenue-generating activities, and is devoting substantially all of its efforts toward technology research and development and to commercially licensing its technology to manufacturers and designers of integrated circuits. The Company has primarily financed operations through private placements of equity and debt securities, the Company’s Initial Public Offering (the “IPO”) which was consummated on August 10, 2016, and subsequent public offerings of its common stock.

 

2. LIQUIDITY AND MANAGEMENT PLANS

 

At September 30, 2021, the Company had cash and cash equivalents of approximately $31.8 million and working capital of approximately $29.3 million. The Company has generated only limited revenues since inception and has incurred recurring operating losses.

 

The Company’s operating plans for the next 12 months include increased spending on research and development headcount, outsourced fabrication and testing, and sales and marketing expenses to drive customer adoption of the Company’s MST technology. Based on the funds it has available as of the date of the filing of this report, the Company believes that it has sufficient capital to fund its current business plans and obligations over, at least, 12 months from the date that these financial statements have been issued. However, as the Company has generated only limited revenue, it is subject to all the risks inherent in the initial organization, financing, expenditures, complications and delays in a new business. Accordingly, the Company may require additional capital, the receipt of which cannot be assured. In the event the Company requires additional capital, there can be no guarantee that funds will be available on commercially reasonable terms, if at all. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its technology, competing technological and market developments, and the need to enter into collaborations with other companies or acquire technologies to enhance or complement its current offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

 

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Significant accounting policies

 

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 19, 2021.

 

Basis of presentation of unaudited condensed financial information

 

The unaudited condensed financial statements of the Company for the three and nine months ended September 30, 2021 and 2020 have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and its results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2020, was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed with the SEC on February 19, 2021. These unaudited condensed financial statements should be read in conjunction with that report.

  

 

  7  

 

 

Adoption of recent accounting standards

 

In December 2019, the FASB issued ASU No. 2019-12, Simplifying Accounting for Income Taxes. This is part of the FASB’s overall initiative to reduce complexity in accounting standards. Amendments include removal of certain exceptions to the general principles of Accounting Standard Codification (“ASC”) 740, Income taxes, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The Company adopted this standard on January 1, 2021 and it did not have a material impact on its financial position, results of operations or financial statement disclosure.

 

Recent accounting standards

 

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). The new guidance eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted earnings per share computation. This guidance is effective as of January 1, 2022 (Early adoption is permitted effective January 1, 2021). The Company is currently evaluating the effect the updated standard will have on its financial position, results of operations or financial statement disclosure.

  

4. REVENUE

 

The Company recognizes revenue in accordance with ASC 606. The amount of revenue that the Company recognizes reflects the consideration it expects to receive in exchange for goods or services and such revenue is recognized at the time when goods or services are transferred and/or delivered to its customers. Revenue is recognized when the Company satisfies a performance obligation by transferring the product or service to the customer. The Company generates revenues from engineering service contracts, integration license agreements and joint development agreements. When the Company’s performance obligation is the promise to grant a license, revenue is recognized either at a point in time or over time.

 

The following table provides information about disaggregated revenue by primary geographical markets and timing of revenue recognition (in thousands):  

                               
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2021     2020     2021     2020  
Primary geographic markets                                
North America   $ –     $ –     $ –     $ 62  
Asia Pacific     –       –       400       –  
Total   $ –     $ –     $ 400     $ 62  
                                 
Timing of revenue recognition                                
Products and services transferred at a point in time   $ –     $ –     $ 400     $ 62  
Products and services transferred over time     –       –       –       –  
Total   $ –     $ –     $ 400     $ 62  

 

Unbilled contracts receivable and deferred revenue

 

Timing of revenue recognition may differ from the timing of invoicing customers. Accounts receivable includes amounts billed and currently due from customers. Unbilled contracts receivable represents unbilled amounts expected to be received from customers in future periods, where the revenue recognized to date exceeds the amount billed, and the right to receive payment is subject to the underlying contractual terms. Unbilled contracts receivable amounts may not exceed their net realizable value and are classified as long-term assets if the payments are expected to be received more than one year from the reporting date.

 

The Company records deferred revenue when revenue will be recognized after invoicing. During the nine months ended September 30, 2020, the Company recognized approximately $37,000 of revenue that was included in deferred revenue as of December 31, 2019.

  

 

  8  

 

 

 

5. BASIC AND DILUTED LOSS PER SHARE

 

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of shares of common stock outstanding and the dilutive common stock equivalent shares outstanding during the period. The Company’s potentially dilutive common stock equivalent shares, which include incremental common shares issuable upon (i) the exercise of outstanding stock options and warrants and (ii) vesting of restricted stock units and restricted stock awards, are only included in the calculation of diluted net loss per share when their effect is dilutive. Since the Company has had net losses for all periods presented, all potentially dilutive securities are anti-dilutive. Accordingly, basic and diluted net loss per share are equal.

 

The following potential common stock equivalents were not included in the calculation of diluted net loss per common share because the inclusion thereof would be anti-dilutive (in thousands): 

               
       
   

Three and Nine Months Ended

September 30,

 
    2021     2020  
Stock Options     2,975       3,463  
Unvested restricted stock     452       716  
Warrants     1       369  
Total     3,428       4,548  

 

 

6. LEASES

 

The Company leases corporate office space in Los Gatos, California. In August 2020, the Company and its landlord amended the lease for this office. This amendment extends the expiration date of the operating lease from January 2021 to January 2026 and increases the space from 3,396 square feet to 4,101 square feet. Under ASC 842, the lease amendment was treated as a separate lease for the new space and a modification of the lease for the original space. An additional right-of-use (“ROU”) asset and lease liability of approximately $681,000 were recorded at the time of the amendment. In January 2021 the additional space became available for use, and the Company recorded an additional ROU asset and corresponding liability of approximately $144,000. The lease liability is based on the present value of the minimum lease payments, discounted using the Company’s estimated incremental borrowing rate of 5.5%. The lease contains escalating payments on the anniversary of the original commencement which are included in the measurement of the initial lease liability. Additional payments based on a change in the Company’s share of the operating expenses, including property taxes and insurance, are recorded as a period expense when incurred.

 

In March 2021, the Company began leasing 474 square feet of office space in Tempe, Arizona. The new lease is classified as an operating lease with an initial term of two years and an option to extend for an additional three years through February 2026. The lease also contains a performance standard for research collaboration with Arizona State University. The agreement requires a minimum value of collaborative research in each year of the lease. The lease is accounted for under ASC 842 and accordingly, the research payments are included in the ROU and lease liability at the commencement. In March 2021, the Company recorded an ROU and associated lease liability of approximately $238,000. The lease liability is based on the present value of the minimum lease payments, discounted using the Company’s estimated incremental borrowing rate of 5.25% over five years, as the Company expects to lease the space through the three-year extension. The lease also contains escalating payments on the anniversary of the original commencement which are included in the measurement of the initial lease liability.

 

 

  9  

 

 

In October 2019, the Company entered into an agreement to lease a tool for use in the development of the Company’s technology. The lease is for five 5 years at $150,000 per month and commenced on August 1, 2021. A prepayment of $450,000 was made in the nine months ended September 30, 2020 which represents the final three monthly payments under the lease and was recorded as a long-term prepaid until the lease commencement. At commencement, the Company recorded an ROU asset of approximately $6.4 million and a corresponding lease liability of approximately $6.0 million. The lease was classified as a financing lease and accordingly, amortization is recorded as a research and development expense in the Company’s condensed statement of operations. Interest expense is also recorded and included in other income or expense in the Company’s condensed statement of operations. The lease liability is based on the present value of the minimum lease payments, discounted using the Company’s estimated incremental borrowing rate of 5.25% at the time of commencement. The lease payment of $150,000 per month includes approximately $30,000 in supplies and maintenance that is recorded as an operating expense and is not included in the valuation of the lease liability. The Company elected to exclude these costs from the asset and related lease liability valuation for this class of assets. These costs will be expensed as operating expenses in the period incurred.

 

Lease expense for operating leases consists of the lease payments recognized on a straight-line basis over the lease term. Expenses for financing leases consists of the amortization expenses recognized on a straight-line basis over the lease term and interest expense. The components of lease costs were as follows (in thousands): 

                       
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2021     2020     2021     2020  
Financing lease costs:                                
Amortization of ROU Assets   $ 211     $ –     $ 211     $ –  
Interest on lease liabilities     52       –       52       –  
Operating lease costs                                
Fixed lease costs     63       30       177       83  
Variable lease costs     –       9       –       36  
Short-term lease costs     10       11       32       28  
Total operating lease costs   $ 336     $ 50     $ 472     $ 147  

 

 

Future minimum payments under non-cancellable leases as of September 30, 2021 were as follows (in thousands): 

           
For the Year Ended December 31,   Financing leases     Operating leases  
Remaining 2021   $ 597     $ 60  
2022     1,436       239  
2023     1,436       271  
2024     1,436       278  
2025 & thereafter     1,914       305  
Total future minimum lease payments     6,819       1,153  
Less imputed interest     (743 )     (130 )
Total lease liability   $ 6,076     $ 1,023  

 

The following table provides supplemental information and non-cash activity related to the Company’s operating and financing leases (in thousands): 

                       
   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
    2021     2020     2021     2020  
Operating cash flow information:                                
Cash paid for amounts included in the measurement of operating lease liabilities   $ 52     $ 41     $ 90     $ 123  
Cash paid for amounts included in the measurement of financing lease liabilities     –       –       –       –  
Non-cash activity:                                
Right-of-use assets obtained in exchange for operating lease obligations   $ –     $ 681     $ 382     $ 681  
Right-of-use assets obtained in exchange for financing lease obligations   $ 6,383     $ –     $ 6,383     $ –  

 

The weighted average remaining discount rate is 5.25% for the Company’s operating and financing leases. The weighted average remaining lease term is 4.4 years for operating leases and 4.8 years for financing leases.

 

  10  

 

 

 

 

7. WARRANTS

 

A summary of warrant activity for the nine months ended September 30, 2021 is as follows (in thousands except per share amounts and contractual term): 

                 
   

Number of

Shares

   

Weighted-

Average

Exercise

Price

   

Weighted-
Average

Remaining

Contractual

Term (In Years)

 
Outstanding at January 1, 2021     320     $ 9.47          
Exercised     (318 )   $ 9.38          
Expired     (1 )   $ 9.38          
Outstanding at September 30, 2021     1     $ 33.75       0.5  

  

The warrants outstanding at September 30, 2021 had an intrinsic value of $0 based on a per-share stock price of $23.09 as of September 30, 2021.

 

On March 17, 2020, 196,602 warrants with an exercise price of $3.75 were set to expire. Prior to the expiration, the Company entered into an agreement with the warrant holders, whereby it modified the terms of the warrants to extend the expiration date until September 17, 2020 in exchange for the removal of a cashless exercise provision. No other terms were modified. Due to this modification, the Company incurred a modification expense of approximately $139,000 that is included in general and administrative expenses on the Condensed Statement of Operations for the nine months ended September 30, 2020. All of the modified warrants were exercised on August 6, 2020.

 

In January 2021, warrants for 317,488 shares were presented for cashless exercises resulting in the issuance of 223,487 shares of common stock.

   

8. STOCK BASED COMPENSATION

 

In May 2017, the Company’s shareholders approved its 2017 Stock Incentive Plan (“2017 Plan”) after its 2007 Stock Incentive Plan (“2007 Plan”) had expired in March 2017. The 2017 Plan provides for the grant of non-qualified stock options and incentive stock options to purchase shares of the Company’s common stock and for the grant of restricted and unrestricted shares. The 2017 Plan provides for the issuance of 3,750,000 shares of common stock. All of the Company’s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the Company’s nonemployee directors and other consultants, advisors and other persons who provide services to the Company are eligible to receive incentive awards under the 2017 Plan. Generally, stock options and restricted stock issued under the 2017 Plan vest over a period of one to four years from the date of grant.

 

The following table summarizes the stock-based compensation expense recorded in the Company’s results of operations during the three and nine months ended September 30, 2021 and 2020 for stock options and restricted stock granted under the 2017 Plan and the 2007 Plan (in thousands): 

                       
   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
    2021     2020     2021     2020  
Research and development   $ 267     $ 319     $ 757     $ 843  
General and administrative     442       470       1,451       1,269  
Selling and Marketing     47       40       126       112  
Total   $ 756     $ 829     $ 2,334     $ 2,224  

  

As September 30, 2021, there was approximately $6.1 million of total unrecognized compensation expense related to unvested share-based compensation arrangements. This cost is expected to be recognized over a weighted-average period of 2.3 years.

 

 

  11  

 

 

The weighted average grant date fair value per share of the options granted under the Company’s 2017 Plan was $13.77 and $15.29 for the three and nine months ended September 30, 2021, respectively. The weighted average grant date fair value per share of the options granted under Company’s 2017 plan was $7.64 and $2.80 for the three and nine months ended September 30, 2020, respectively.

 

The following table summarizes stock option activity during the nine months ended September 30, 2021 (in thousands except exercise prices and contractual terms): 

                       
   

Number of

Shares

   

Weighted-

Average

Exercise

Prices per Share

   

Weighted-
Average

Remaining

Contractual

Term (In Years)

    Intrinsic
Value 		 
Outstanding at January 1, 2021     3,446     $ 5.97                  
Granted     153     $ 21.77                  
Exercised     (506 )   $ 6.14                  
Forfeited     (118 )   $ 4.50                  
Outstanding at September 30, 2021     2,975     $ 6.81       6.03     $ 48,544  
Exercisable at September 30, 2021     2,310     $ 6.47       5.36     $ 38,471  

 

During the nine months ended September 30, 2021, the Company granted options under the 2017 Plan to purchase approximately 153,000 shares of its common stock to its employees. The fair value of these options was approximately $2.3 million at the time of grant.

  

The Company issues restricted stock to employees, directors and consultants and estimates the fair value based on the closing price on the day of grant. The following table summarizes all restricted stock activity during the nine months ended September 30, 2021 (in thousands except per share data): 

           
   

Number of

Shares

   

Weighted-

Average

Grant Date
Fair Value per Share

 
Outstanding at January 1, 2021     642     $ 4.43  
Granted     89     $ 21.02  
Vested     (216 )   $ 6.39  
Forfeited     (63 )   $ 5.69  
Outstanding non-vested shares at September 30, 2021     452     $ 6.58  

  

During the nine months ended September 30, 2021 the Company granted approximately 89,000 restricted stock awards under the 2017 Plan to its employees and directors. The fair value of these awards was approximately $1.9 million at the time of grant.

 

During the nine months ended September 30, 2021, approximately 63,000 restricted stock awards were forfeited and reissued under the Company’s equity compensation plan. 

 

9. PROVISION FOR INCOME TAXES

 

The Company recorded a provision for income taxes of approximately $17,000 and $48,000 during the three and nine months ended September 30, 2021, respectively. The provision is for withholding of income taxes accrued in foreign jurisdictions where we have income. The Company recorded the provision in accordance with ASC 740 using its estimated annual tax rate and applied it to the net loss for the three and nine months ended September 30, 2021.

 

 

  12  

 

 

 

 

10. COMMITMENTS AND CONTINGENCIES

  

Litigation, Claims and Assessments

 

The Company may be subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of September 30, 2021, or through the date these financial statements have been issued.

 

11. SUBSEQUENT EVENTS

 

Management has evaluated subsequent events and transactions through the date these financial statements were issued.

  

 

 

 

 

 

 

 

 

  13  

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of the financial condition and results of operations of Atomera Incorporated should be read in conjunction with our unaudited condensed financial statements and the accompanying notes that appear elsewhere in this filing. Statements in this Quarterly Report on Form 10-Q include forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. Although forward-looking statements in this Quarterly Report reflect the good-faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks, uncertainties, and changes in condition, significance, value and effect, including those risk factors set forth under the heading “Risk Factors” within our Annual Report on Form 10-K filed with the SEC on February 19, 2021, quarterly reports on Form 10-Q and our current reports on Form 8-K. Such risks, uncertainties and changes in condition, significance, value and effect could cause our actual results to differ materially from those expressed herein and in ways not readily foreseeable. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report and are based on information currently and reasonably known to us. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report. Readers are urged to carefully review and consider the various disclosures made in this Quarterly Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

 

Overview

 

We are engaged in the business of developing, commercializing and licensing proprietary materials, processes and technologies for the $450+ billion semiconductor industry. Our lead technology, named Mears Silicon TechnologyTM, or MST®, is a thin film of reengineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the most widely used transistor type in the semiconductor industry. MST is our proprietary and patent-protected performance enhancement technology that we believe addresses a number of key engineering challenges facing the semiconductor industry. We believe that by incorporating MST, transistors can be made smaller, with increased speed, reliability and energy efficiency. In addition, since MST is an additive and low-cost technology, we believe it can be deployed on an industrial scale, with equipment commonly used in semiconductor manufacturing. We believe that MST can improve existing products due to the physical properties of the film and can also enable customers to design products with performance, power and scaling characteristics that are not possible using their current process technologies. We believe that MST can be incorporated into a wide range of the most common types of semiconductor products, including analog, logic, optical and memory integrated circuits. 

 

We do not intend to design or manufacture integrated circuits directly. Instead, we develop and license technologies and processes that we believe offer the designers and manufacturers of integrated circuits a low-cost solution to the industry’s need for greater performance and lower power consumption. Our customers and partners include: 

 

  · foundries, which manufacture integrated circuits on behalf of fabless manufacturers;
     
  ·  integrated device manufacturers, or IDMs, which are the fully integrated designers and manufacturers of integrated circuits;
     
  ·  fabless semiconductor manufacturers, which are designers of integrated circuits that outsource the manufacture of their chips to foundries;
     
  ·  original equipment manufacturers, or OEMs, which manufacture the epitaxial, or EPI, deposition machines used to deposit semiconductor layers, such as the MST film onto the silicon wafer; and
     
  ·

electronic design automation companies, which make tools used throughout the industry to simulate the performance of semiconductor products using different materials, design structures and process technologies.

 

  

 

  14  

 

 

Our commercialization strategy is to generate revenue through licensing arrangements whereby foundries, IDMs and fabless semiconductor manufacturers pay us a license fee for their right to use MST technology in the manufacture of silicon wafers as well as a royalty for each silicon wafer or device that incorporates our MST technology. To date we have generated revenue from (i) a joint development agreement, or JDA, with a leading semiconductor provider that includes license grants and engineering services, (ii) licensing agreements with two IDMs and one fabless manufacturer and (iii) engineering services provided to foundries, IDMs and fabless companies.

 

We were organized as a Delaware limited liability company under the name Nanovis LLC on November 26, 2001. On March 14, 2007, we converted to a Delaware corporation under the name Mears Technologies, Inc. On January 12, 2016, we changed our name to Atomera Incorporated.

 

On May 15, 2020, we closed an underwritten public offering of 2,024,000 shares of common stock at a public offering price of $5.00 per share, resulting in approximately $9.4 million of net proceeds to us after deducting underwriting commission and other offering expenses.

 

On September 2, 2020, we entered into an Equity Distribution Agreement with Craig-Hallum Capital Group LLC, as agent, under which we could offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $25.0 million in an “at-the-market” or ATM offering, to or through the agent. We announced the completion of this offering on January 5, 2021 after 2,221,575 shares had been sold at an average price per share of approximately $11.25, resulting in approximately $24.2 million of net proceeds to us after deducting commissions and other offering expenses.

   

Results of Operations

 

Revenues. To date, we have only generated limited revenue from customer engagements through a JDA, integration engineering services and integration license agreements. In the future, we expect to collect increased fees from license agreements, which in some cases may be part of a JDA, and royalties from customer sales of products that incorporate our MST technology. Our JDA includes the grant of an upfront, paid manufacturing license allowing the customer to install the recipe for our MST film into a tool in their fab and to fabricate semiconductor wafers incorporating MST, as well as development milestones that, if achieved, could result in additional revenue to Atomera. However, the JDA does not confer commercial distribution rights. Revenue from the grant of licenses to MST is recognized either at a point in time or over time, depending on the nature of the grant. We have determined that the limited manufacturing license granted to our JDA customer when we delivered the MST recipe was distinct from any obligations to provide other goods or services and was a right to use our intellectual property and therefore recognized revenue at the point in time when we delivered the recipe.

 

Our integration services consist of depositing our MST film on semiconductor wafers, delivering such wafers to customers to finalize building devices, and performing tests for customers evaluating MST. The integration license agreements we have entered into to date grant the licensees the right to build products that integrate our MST technology deposited by us onto their semiconductor wafers, but the agreements do not grant the licensees the rights to manufacture on their site or to sell products incorporating MST. For revenue recognition purposes, we have determined that the grant of rights in integration licenses is not distinct from the delivery of integration services, and therefore revenue from both integration licenses and integration services is recognized as the services are provided to the customer. In general, this is proportionate to the delivery of MST processed wafers to the customer, but if the agreements do not specify a time and quantity of wafer delivery, we will record revenue over the period of time of which we anticipate delivering an estimated quantity of wafers.

  

Revenue for each of the three months ended September 30, 2021 and 2020 was $0. Revenue for the nine months ended September 30, 2021 and 2020 was approximately $400,000 and $62,000, respectively.

 

Cost of Revenue. Cost of revenue consists of costs of materials, as well as direct compensation and expenses incurred to provide integration engineering services. Cost of revenue was $0 for each of the three months ended September 30, 2021 and 2020. Cost of revenue was approximately $0 and $13,000 for the nine months ended September 30, 2021 and 2020, respectively. We anticipate that our cost of revenue will vary substantially depending on the mix of integration license and integration engineering services and the nature of products and/or services delivered in each customer engagement.

  

 

  15  

 

 

Operating Expenses Operating expenses consist of research and development, general and administrative, and selling and marketing expenses. For the three months ended September 30, 2021 and 2020 our operating expenses totaled approximately $4.1 million and $3.6 million, respectively. For the nine months ended September 30, 2021 and 2020, our operating expenses totaled approximately $11.9 million and $11.1 million, respectively.

  

Research and development expense. To date, our operations have focused on the research, development, patent protection, and commercialization of our processes and technologies related to MST. Our research and development costs primarily consist of payroll and benefit costs for our engineering staff and costs of outsourced fabrication and metrology of semiconductor wafers incorporating our MST technology.

 

 Research and development costs were approximately $2.2 and $2.0 million for the three months ended September 30, 2021 and 2020, respectively representing an increase of approximately $183,000, or 9%. This increase in primarily due to our new tool lease that began in August 2021.

 

 For the nine months ended September 30, 2021 and 2020, we incurred approximately $6.5 million and $6.2 million, respectively, of research and development expense, an increase of approximately $333,000 or 5%. The increase in research and development expense is primarily due to additional headcount and the new tool lease, offset by a decrease in outsourced research and development costs. 

 

General and administrative expense. General and administrative expenses consist primarily of payroll and benefit costs for administrative personnel, office-related costs and professional fees. General and administrative costs were approximately $1.6 and $1.3 million for the three months ended September 30, 2021 and 2020, respectively. The increase of approximately $315,000, or 24% is primarily due to increases in patent-related legal fees and higher insurance costs.

 

General and administrative costs for the nine months ended September 30, 2021 and 2020 were approximately $4.7 million and $4.2 million, respectively, representing an increase of approximately $409,000, or 10%. The increase in costs was primarily due to increases of approximately $214,000 in insurance costs, approximately $90,000 in rent costs and approximately $182,000 in stock-based compensation, offset in part by a decrease of approximately $111,000 in professional fees.

 

Selling and marketing expense. Selling and marketing expenses consist primarily of salary and benefits for our sales and marketing personnel. Selling and marketing expenses for the three months ended September 30, 2021 and 2020 were approximately $267,000 and $208,000, respectively, representing an increase of approximately $59,000, or 28%. The increase in costs is primarily related to increased spending in new marketing initiatives.

 

 Selling and marketing expenses for the nine months ended September 30, 2021 and 2020 were approximately $670,000 and $648,000, respectively, representing an increase of approximately $22,000, or 3%. The increase in costs is primarily related to increased spending in new marketing initiatives offset by lower payroll and related expenses.

 

 Interest income. Interest income for the three months ended September 30, 2021 and 2020 was approximately $2,000 and $1,000, respectively. Interest income for the nine months ended September 30, 2021 and 2020 was approximately $7,000 and $41,000, respectively. Interest income for each period related to interest earned on our cash and cash equivalents. The decrease in interest income was due to the fall in interest rates during 2020 and into 2021.

 

Interest expense. Interest expense for the three and nine months ended September 30, 2021 and 2021 was approximately $52,000 for each period. There was no interest expense recorded for the three and nine months ended September 30, 2020. Interest expense is related to the new tool financing lease entered into in August 2021.

 

Provision for income taxes. The provision for income taxes for the three months ended September 30, 2021 and 2020 was approximately $17,000 and $0, respectively. The provision for income taxes for the nine months ended September 30, 2021 and 2020 was approximately $48,000 and $0, respectively. Our provision is for income taxes due to a foreign country arising from withholding taxes imposed on payments received for revenue.

 

 

  16  

 

 

Cash Flows from Operating, Investing and Financing Activities

  

Net cash used in operating activities of approximately $9.4 million for the nine months ended September 30, 2021 resulted primarily from our net loss of approximately $11.5 million and an increase of approximately $297,000 in prepaid expenses and other assets, offset by approximately $2.3 million of stock-based compensation.

 

Net cash used in operating activities of approximately $9.1 million for the nine months ended September 30, 2020 resulted primarily from our net loss of approximately $11.0 million adjusted by approximately $2.2 million in stock-based compensation expense, offset by an increase of approximately $499,000 in prepaids and other assets.

  

Net cash used in investing activities of approximately $102,000 for the nine months ended September 30, 2021 and approximately $56,000 for the nine months ended September 30, 2020 consisted of the purchase of computers, lab tools and leasehold improvements for the remodeled Los Gatos office space and new Tempe office space.

 

 Net cash provided by financing activities of approximately $3.4 million for the nine months ended September 30, 2021 related to the exercise of approximately 506,000 stock options and net proceeds from our at-the-market offering which began in September 2020 and concluded in January 2021.

 

Net cash provided by financing activities of approximately $19.6 million for the nine months ended September 30, 2020 was primarily related to the net proceeds from our underwritten public offering in May 2020, proceeds from our ATM program in September 2020 and the exercise of approximately 386,000 warrants and approximately 136,000 stock options during this nine month period.

 

Liquidity and Capital Resources

 

As of September 30, 2021, we had cash and cash equivalents of approximately $31.8 million and working capital of approximately $29.3 million. For the nine months ended September 30, 2021, we had a net loss of approximately $11.5 million and used approximately $9.4 million of cash and cash equivalents in operations. Since inception, we have incurred recurring operating losses.

 

We believe that our available working capital is sufficient to fund our presently forecasted working capital requirements for, at least, the next 12 months following the date of the filing of this report. However, the semiconductor industry is generally slow to adopt new manufacturing process technologies and conducts long testing and qualification processes which we have limited ability to control, and there can be no assurance of the timing of our receipt of meaningful amounts of revenue.

  

Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our MST technology, competing technological and market developments, and the need to enter into collaborations with other companies or acquire technologies to enhance or complement our current offerings. If we are not able to generate sufficient revenue from license fees and royalties in a timeframe that satisfies our cash needs, we will need to raise more capital. In the event we require additional capital, we will endeavor to acquire additional funds through various financing sources, including follow-on equity offerings, debt financing and joint ventures with industry partners. In addition, we will consider alternatives to our current business plan that may enable to us to achieve revenue-producing operations and meaningful commercial success with a smaller amount of capital. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements or issued guarantees to third parties.

  

 

  17  

 

 

Recent Accounting Standards

 

We are required to adopt certain new accounting standards, see note 3 to the condensed financial statements included in Item 1 of this Form 10-Q.

 

Critical Accounting Policies

 

There have been no changes to our critical accounting policies from those included in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 19, 2021

 

Item 3. Quantitative and Qualitative Disclosure about Market Risk.

 

Not applicable.

  

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our chief executive officer and principal financial and accounting officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based on this evaluation, management concluded that our disclosure controls and procedures were effective as of September 30, 2021.

 

Changes in Internal Control over Financial Reporting

 

There have not been any changes to our internal controls over financial reporting (as defined by Rule 13a-15(f) and 15(d)-15(f) under the Exchange Act) during the three-month period ended September 30, 2021 that have material affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

  

 

  18  

 

 

PART II. Other Information

 

Item 1A. Risk Factors

 

The primary risk factors affecting our business have not changed materially from the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 19, 2021.

 

Item 5. Other Information

 

(b)       On October 21, 2021, our Board of Directors, or Board, approved and adopted our First Amended and Restated Bylaws, or Amended Bylaws, of the Corporation. Among the changes in the Amended Bylaws is an advance notice requirement for any stockholder nominations or business at an annual or special meeting of stockholders, set forth in Section 1.13 of the Amended Bylaws.

 

Pursuant to Section 1.13 of our Amended Bylaws, if you wish to bring a proposal before the stockholders or nominate a director at our 2022 annual meeting of stockholders, but you are not requesting that your proposal or nomination be included in next year’s proxy materials, you must deliver such proposal or nomination to our President or our principal executive officer at our principal place of business, in writing, not later than the close of business on February 5, 2022 nor earlier than the close of business on January 6, 2022. However, if our 2022 annual meeting of stockholders is not held between April 6, 2022 and June 5, 2022, to be timely, notice by the stockholder must be received no earlier than the close of business on the 120th day prior to the 2022 annual meeting of stockholders and not later than the close of business on the later of the 90th day prior to the 2022 annual meeting of stockholders or the 10th day following the day on which public announcement of the date of the 2022 annual meeting of stockholders is first made. You are also advised to review our Amended Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations.

 

The person presiding over our 2022 annual meeting of stockholders may determine, if the facts warrant, that a proposal or nomination has not been properly brought before the meeting and, therefore, may not be considered at the meeting. In addition, the proxy solicited by the Board for the 2022 annual meeting of stockholders will confer discretionary voting authority with respect to (i) any proposal presented by a stockholder at that meeting for which we have not been provided with timely notice and (ii) any proposal made in accordance with our Amended Bylaws, if the 2022 annual meeting proxy statement briefly describes the matter and how management’s proxy holders intend to vote on it, and if the stockholder does not comply with the requirements of Rule 14a-4(c)(2) promulgated under the Securities Exchange Act of 1934.

 

Item 6. Exhibits

 

The following is a list of exhibits filed as part of this Report on Form 10-Q:

 

Exhibit

No.

  Description   Method of filing
         
3.1   First Amendment and Restated Bylaws of Atomera Incorporated   Incorporated by reference from Registrant’s Current Report on Form 8-K filed on October 27, 2021
         
31.1   Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   Filed electronically herewith  
         
31.2   Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   Filed electronically herewith  
         
32.1   Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).   Filed electronically herewith  
         
101.INS   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)   Filed electronically herewith  
101.SCH   Inline XBRL Taxonomy Extension Schema Document   Filed electronically herewith  
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document   Filed electronically herewith  
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document   Filed electronically herewith  
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document   Filed electronically herewith  
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document   Filed electronically herewith  
104   Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).   Filed electronically herewith  
         

  

 

 

  19  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and the on the date indicated.

 

  ATOMERA INCORPORATED.  
     
Date: November 1, 2021 By: /s/ Scott A. Bibaud  
    Scott A. Bibaud
Chief Executive Officer, 		 
    (Principal Executive Officer)  
    and Director  
       
       
Date: November 1, 2021 By: /s/ Francis B. Laurencio  
    Francis B. Laurencio  
    Chief Financial Officer  
    (Principal Financial and  
    Accounting Officer)  

 

 

 

  20  

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, Scott A. Bibaud, certify that:

 

(1) I have reviewed this Form 10-Q of Atomera Incorporated (the “Company”);
   
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
   
(4) The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and15d- 15(f)) for the company and have:
     
  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; And
     
(5) The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
     
  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

  ATOMERA INCORPORATED
     
     
Date: November 1, 2021 By: /s/ Scott A. Bibaud
    Scott A. Bibaud, Chief Executive Officer

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Francis B. Laurencio, certify that:

 

(1) I have reviewed this Form 10-Q of Atomera Incorporated (the “Company”);
   
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
   
(4) The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and15d- 15(f)) for the company and have:
     
  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; And
     
(5) The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
     
  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

  ATOMERA INCORPORATED
     
     
Date: November 1, 2021 By: /s/ Francis B. Laurencio
   

Francis B. Laurencio, Chief Financial Officer

(Principal Financial Officer)

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18

U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Atomera Incorporated (the “Company”) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott A. Bibaud, the Chief Executive Officer, and Francis B. Laurencio, the Chief Financial Officer, of the Company, respectively, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

By: /s/ Scott A. Bibaud   Dated: November 1, 2021
  Scott A. Bibaud    
  Title: President and Chief Executive Officer    
       
By: /s/ Francis B. Laurencio   Dated: November 1, 2021
  Francis B. Laurencio    
  Title:  Chief Financial Officer    

 

This certification is made solely for the purposes of 18 U.S.C. Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.